1. 201PEfficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial. (24th November 2019) Authors: Pang, J S-T; Shore, N; Smith, M R; Tammela, T L; Ulys, A; Vjaters, E; Polyakov, S; Jievaltas, M; Luz, M; Alekseev, B; Kuss, I; Le Berre, M-A; Snapir, A; Sarapohja, T; Fizazi, K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 805PA phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. (23rd October 2018) Authors: Fizazi, K; Hussain, M; Saad, F; Shore, N; De Giorgi, U; Efstathiou, E; Ferreira, U; Ivashchenko, P; Madziarska, K; Al-Adhami, M; Modelska, K; Phung, D; Steinberg, J; Sternberg, C N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 830PSynthetic DNA immunotherapy in biochemically relapsed prostate cancer. (23rd October 2018) Authors: Shore, N; Heath, E I; Nordquist, L T; Cheng, H; Bhatt, K; Morrow, M; McMullan, T; Kraynyak, K; Lee, J; Sacchetta, B; Liu, L; Rosencranz, S; Tagawa, S T; Appleman, L J; Tutrone, R; Garcia, J; Whang, Y; Kelly, W; Csiki, I; Bagarazzi, M L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 834PInterim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer. (23rd October 2018) Authors: Saad, F; Chi, K N; Shore, N; Graff, J N; Posadas, E M; Freeman, S; Tryon, J; Trudel, G C; de Jong, J; Meltzer, J; Zhao, X; Tran, N; Rezazadeh, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Advances in targeted alpha therapy for prostate cancer. (16th August 2019) Authors: De Vincentis, G; Gerritsen, W; Gschwend, J E; Hacker, M; Lewington, V; O'Sullivan, J M; Oya, M; Pacilio, M; Parker, C; Shore, N; Sartor, O Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. LBA8PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. (24th November 2019) Authors: Sandhu, S K; Hussain, M; Mateo, J; Fizazi, K; Saad, F; Shore, N; Chi, K; Sartor, O; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; Twardowski, P; Mehra, N; Goessl, C; Kang, J; Burgents, J; Wu, W; Kohlmann, A; Adelman, C; de Bono, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (23rd October 2017) Authors: Armstrong, A J; Antonarakis, E S; Taplin, M -E; Kelly, W K; Beltran, H; Fizazi, K; Dahut, W L; Shore, N; Slovin, S; George, D; Carducci, M A; Corn, P; Danila, D; Dreicer, R; Heath, E; Rathkopf, D; Liu, G; Nanus, D; Stein, M; Smith, M R Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗